Document Detail

MedLine Citation:
PMID:  22879009     Owner:  NLM     Status:  In-Data-Review    
We have defined the Zymogen Protein C (ZPC) to Activated Protein C (APC) process as the "silver bullet" of blood anticoagulation. This definition suggests that the anticoagulation activity occurs when and where it is needed, resulting in local anticoagulation without enhanced bleeding. It is important for man to be able to manufacture an inexpensive ZPC product or to find a substitute drug to duplicate one of God's natural anticoagulant/antithrombotic processes, in vivo, in human blood. After intense research and at great expense scientists have not been able to produce a safe anticoagulant. All products that are now being used can cause bleeding even if dosing is carefully monitored. In fact many professionals in the health care and the pharmaceutical industries define an anticoagulant as a drug that "does" cause bleeding. This results in a large financial burden that has been placed on the health care industry because of necessary emergency treatments for dangerous occurrences. In addition, many patients are dying annually due to internal and external bleeds created or enhanced by presently administered anticoagulants. Since there are no safe drugs available it is necessary to use the existing products when a medical condition calls for an anticoagulant. This paper will discuss the ZPC process and why its mechanistic design is one of nature's unique defenses against unwanted blood clotting. The prevention and lysis of clots allows normal blood flow and therefore results in the required tissue oxygenation for cell function and survival. If clinical research is carried out with great care it could uncover other uses of ZPC that will allow safer medical procedures, in addition to its use with standard PC deficiency cases. An important example might be for some brain surgeries where the use of existing anticoagulants is unsafe because of potential bleeds. Clinical research could reveal an efficacious ZPC level (for instance, 125, 150, or 200% of normal) that would prevent dangerous clotting situations from occurring without unnecessary bleeding.
Duane F Bruley; Michael B Streiff
Related Documents :
18849539 - Efflux of iron from the cerebrospinal fluid to the blood at the blood-csf barrier: effe...
22391639 - Disruption of intracardiac flow patterns in the newborn infant.
7457239 - Cerebrospinal fluid edema and its sequelae in hydrocephalus.
1878529 - Stability of diltiazem in different biological fluids.
22401759 - Contributions of dynamic venous blood volume versus oxygenation level changes to bold f...
16325339 - Dose-dependent transthyretin inhibition of t4 uptake from cerebrospinal fluid in sheep.
15842209 - Cesarean section: is pretransfusion testing for red cell alloantibodies necessary?
1971539 - Systemic effects of three beta-blocker eyedrops: comparison in healthy volunteers of be...
8535589 - Organisation of blood transfusion services.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Advances in experimental medicine and biology     Volume:  765     ISSN:  0065-2598     ISO Abbreviation:  Adv. Exp. Med. Biol.     Publication Date:  2013  
Date Detail:
Created Date:  2012-08-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0121103     Medline TA:  Adv Exp Med Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  15-21     Citation Subset:  IM    
Synthesizer, Inc., 2773 Westminster Road, Ellicott City, MD, 21043, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Kidney EPO expression during chronic hypoxia in aged mice.
Next Document:  Canonical correlation analysis in the study of cerebral and peripheral haemodynamics interrelations ...